Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema
ABSTRACT Background Garadacimab, a first‐in‐class, recombinant monoclonal antibody targeting activated FXII, is available in Germany for long‐term prophylaxis (LTP) of hereditary angioedema (HAE) since March 2025. We aimed to examine garadacimab real‐life treatment outcomes at our Berlin Angioedema Center of Reference...